The themes Evolus is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Evolus, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
EOLS · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$7.44+9.2%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $330M to $337M for Fiscal year 2026 — up 12.2% on a year earlier
Just reported
From Evolus's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$78M
+13% y/y
-7.3% q/q
Guided
—
No guide given
Actual
-$0.19
Guided
—
No guide given
Actual
-$8.4M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade B
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 28 quarters of Evolus, Inc.’s grade history. The other 26 go back to February 2020.